These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25503797)

  • 1. The evolving use of radioiodine therapy in differentiated thyroid cancer.
    Mayson SE; Yoo DC; Gopalakrishnan G
    Oncology; 2015; 88(4):247-56. PubMed ID: 25503797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine ablation: when and how.
    Ambrosetti MC; Colato C; Dardano A; Monzani F; Ferdeghini M
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):473-81. PubMed ID: 19910900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.
    Pryma DA; Mandel SJ
    J Nucl Med; 2014 Sep; 55(9):1485-91. PubMed ID: 25134528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on recent developments in the therapy of differentiated thyroid cancer.
    Middendorp M; Grünwald F
    Semin Nucl Med; 2010 Mar; 40(2):145-52. PubMed ID: 20113682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.
    Molinaro E; Pieruzzi L; Viola D
    J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differentiated thyroid cancer -- 2009].
    Konrády A
    Orv Hetil; 2011 Jan; 152(5):163-70. PubMed ID: 21247857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine treatment for malignant thyroid disease.
    Berg G
    Acta Oncol; 2006; 45(8):1041-5. PubMed ID: 17118836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
    Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
    Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
    Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
    Perros P
    J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.